Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Heart Failure V: Medical Management

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...

Heart Failure Drugs: Diuretics

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...

Antihypertensive Drugs: Angiotensin II Receptor Blockers

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...

Heart Failure Drugs: β-Blockers

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...

Dose-Response Relationship: Potency and Efficacy

Dose-Response Relationship: Potency and Efficacy

The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it produces...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Changes in quality of life in patients with atrial fibrillation and central sleep apnea treated with transvenous phrenic nerve stimulation.

Sleep medicine·2026

Same author

Clinical and financial impact of sleep disordered breathing on heart failure admissions.

Sleep & breathing = Schlaf & Atmung·2023

Same author

Transvenous phrenic nerve stimulation for central sleep apnea is safe and effective in patients with concomitant cardiac devices.

Heart rhythm·2020

Same author

Novel phrenic nerve stimulator treats Cheyne-Stokes respiration: polysomnographic insights.

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine·2020

Same author

Optimal Medical Therapy Prescribing Patterns and Disparities Identified in Patients with Acute Coronary Syndromes at an Academic Medical Center in an Area with High Coronary Heart Disease-Related Mortality.

American journal of cardiovascular drugs : drugs, devices, and other interventions·2018

Same author

In patients with heart failure the burden of central sleep apnea increases in the late sleep hours.

Sleep·2018

Search research articles

Related Experiment Video

Updated: Jul 9, 2026

Cardiac Pressure-Volume Loop Analysis Using Conductance Catheters in Mice

Cardiac Pressure-Volume Loop Analysis Using Conductance Catheters in Mice

Published on: September 17, 2015

Candesartan in heart failure.

Toni L Ripley¹, Jennifer S Chonlahan, Robin E Germany

¹University of Oklahoma College of Pharmacy, Oklahoma City, OK 73190, USA. toni-ripley@ouhsc.edu

Clinical Interventions in Aging

|December 1, 2007

Summary

This summary is machine-generated.

Candesartan cilexetil effectively treats systolic heart failure. While safe and well-tolerated, its efficacy in diastolic heart failure requires further investigation.

Related Experiment Videos

Last Updated: Jul 9, 2026

Cardiac Pressure-Volume Loop Analysis Using Conductance Catheters in Mice

Cardiac Pressure-Volume Loop Analysis Using Conductance Catheters in Mice

Published on: September 17, 2015

Area of Science:

Cardiology
Pharmacology

Background:

Candesartan cilexetil is a selective angiotensin II receptor blocker (ARB).
It is approved for heart failure treatment.
This review evaluates its use in heart failure patients.

Purpose of the Study:

To review the evidence for candesartan cilexetil in heart failure.
To assess its efficacy and safety in different heart failure types.

Main Methods:

Literature search of MEDLINE using OVID and PubMed.
Inclusion of pharmacologic, pharmacokinetic, and clinical trial data.

Main Results:

Clinical evidence supports candesartan's use in systolic heart failure.
Non-significant results were observed for diastolic heart failure.
Common adverse events included hyperkalemia, renal dysfunction, and hypotension.

Conclusions:

Candesartan cilexetil is a safe and effective treatment for systolic heart failure.
Further research is needed on ARBs combined with ACE inhibitors.
Efficacy data for other ARBs is pending.